- cafead   Mar 11, 2024 at 12:02: PM
via Incyte has laid down a marker in its pursuit of Regeneron and Sanofi’s Dupixent in prurigo nodularis, linking its oral challenger to significant improvements in itch and disease severity in a phase 2 study.
article source
article source